Renal Insufficiency And Cardiovascular Events
NCT00715481 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15628
Last updated 2015-02-10
Summary
Reduced glomerular filtration rate (GFR) has been recently shown to be a powerful predictor of cardiovascular morbidity and mortality in the general population, independent of traditional cardiovascular risk factors.
This observational study is aimed at assessing the association of reduced estimated GFR with cardiovascular morbidity and mortality in a large italian population (at least 15,000 subjects) of type 2 diabetic outpatients over a 4-year follow-up.
Conditions
Sponsors & Collaborators
-
Italian Society of Diabetology
collaborator OTHER -
Diabetic Nephropathy Study Group
lead OTHER
Principal Investigators
-
Giuseppe Pugliese, MD, PhD · Diabetic Nephropathy Study Group
-
Anna Solini, MD, PhD · Diabetic Nephropathy Study Group
Eligibility
- Min Age
- 40 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-06-30
- Primary Completion
- 2008-11-30
- Completion
- 2015-02-28
Countries
- Italy
Study Locations
More Related Trials
-
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
NCT00976495 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
NCT02065791 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients
NCT06365541 ·Status: RECRUITING ·Phase: PHASE4
-
Diabetic Patients With End-Stage Renal Disease
NCT00435786 ·Status: COMPLETED
-
Renal Impairment in Type 2 Diabetic Subjects
NCT00554450 ·Status: COMPLETED ·Phase: PHASE1
-
Mechanisms Underlying SGLT2i Kidney Effect in DKD Progression
NCT07270198 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)
NCT02818192 ·Status: RECRUITING
-
Predicting Response to Incretin Based Agents in Type 2 Diabetes
NCT01503112 ·Status: COMPLETED
-
Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria
NCT00320879 ·Status: COMPLETED ·Phase: PHASE4
-
PeRsOnalising Treatment Of Diabetic Nephropathy:
NCT03509454 ·Status: COMPLETED
-
TRENDY Follow-up: Study on Endothelial Function in Subjects With Type 2 Diabetes Mellitus
NCT00905528 ·Status: COMPLETED
-
Dapagliflozin in Non-diabetic Stage IV CKD
NCT04794517 ·Status: COMPLETED ·Phase: PHASE2
-
Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND)
NCT00157586 ·Status: COMPLETED ·Phase: PHASE3
-
Telmisartan Promotes the Differentiation of Monocytes Into Macrophages M2 in Diabetic Nephropathy?
NCT02768948 ·Status: COMPLETED ·Phase: NA
-
Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease
NCT01101269 ·Status: TERMINATED ·Phase: NA
-
Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)
NCT04930549 ·Status: COMPLETED ·Phase: PHASE2
-
To Improve the Ability of Early Screening and Diagnosis in Patients With Diabetic Nephropathy
NCT05047471 ·Status: UNKNOWN
-
Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy
NCT00157508 ·Status: TERMINATED ·Phase: PHASE2
-
A Glomerular Filtration Rate (GFR) Measuring Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
NCT01572610 ·Status: TERMINATED ·Phase: PHASE2
-
Treatment of Patients With Diabetic Kidney Disease
NCT06187493 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy
NCT06068439 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
The Incretin Effect in Patients With Kidney Impairment
NCT01327378 ·Status: COMPLETED
-
Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes
NCT06532682 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe
NCT04589351 ·Status: UNKNOWN ·Phase: PHASE3
-
Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study
NCT06954090 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4